CCL2

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

Retrieved on: 
星期四, 三月 7, 2024
Queen Square, Doctor of Philosophy, Aes, TREM, CXCL8, CXCL1, Blood, IL-6, Cerebrospinal fluid, Inflammation, Neuroinflammation, NLRP3, Șaeș, Fibrinogen, Volunteering, Risk, Human, Biomarker, AFL, CRP, Patient, Pharmacokinetics, Disease, DSM-IV codes, MRCP, MBBS, Brain, CCL2, Mouse, Face, Pharmaceutical industry

IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.

Key Points: 
  • IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.
  • In addition, reductions in neurodegenerative markers were also observed following oral dosing of NT-0796, including NfL and soluble TREM (sTREM2).
  • The correlation between Parkinson’s disease and neuroinflammation is well-documented, with alpha-synuclein fibrils triggering microglial NLRP3 activation, leading to neuroinflammation and subsequent neurodegeneration.
  • This is the inaugural demonstration of an NLRP3 inhibitor’s potential to not only address Parkinson’s disease but also offer a broader impact on neurodegenerative diseases.

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Retrieved on: 
星期三, 一月 17, 2024
CXCL10, NK, Tumor microenvironment, CCL2, Chemokine, Patient, Radiation, Cytokine, Merck & Co., CCL3, Cancer, Immunotherapy, Cytokine release syndrome, CRS, Blood, Safety, CCL4, VISTA, Immunosuppression, Biomarker, Pembrolizumab, Merck, Clinical trial, TME, Infrared spectroscopy correlation table, DLT, Trial of the century, IL-6, Pharmaceutical industry

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking immunotherapy, cleared the first four monotherapy dose levels and the first cohort in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level. Additionally, KVA12123 demonstrates robust and dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, demonstrating on target effects of blocking VISTA.

Key Points: 
  • Additionally, KVA12123 demonstrates robust and dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, demonstrating on target effects of blocking VISTA.
  • “We are encouraged with the efficacy-related biomarker data that demonstrate on-target activity of KVA12123 in our Phase 1/2 clinical trial.
  • To guide the recommended Phase 2 dose (RP2D) decision, Kineta developed a proprietary assay to evaluate VISTA RO on immune cells from patients in the clinical trial.
  • The drug has been very well tolerated in patients,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.

Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies

Retrieved on: 
星期四, 八月 31, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, IIT, Host response to cancer therapy, CCL2, Clinical trial, Inflammation, Biomarker, COYA, Oxidative stress, HIV disease progression rates, Patient, Coya, Structure factor, Blood, Neurodegenerative disease, Therapy, ALS, Neuroinflammation, Disease, Pharmaceutical industry, Medical imaging, Regulatory T cell

The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients (n = 30) and healthy controls (n=10) and from two investigator-initiated clinical studies (IIT) (n=11).

Key Points: 
  • The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients (n = 30) and healthy controls (n=10) and from two investigator-initiated clinical studies (IIT) (n=11).
  • In the IIT studies, patients were treated with expanded Treg cell therapy in combination with low-dose interleukin-2 (IL-2).
  • As previously reported, patients from these two trials experienced amelioration of disease progression with corresponding increased Treg numbers and suppressive function.
  • Evidence strongly supports the role of inflammation and oxidative stress in the severity and rate of disease progression in ALS.

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer's Disease

Retrieved on: 
星期三, 六月 7, 2023
SAB, Houston Methodist Hospital, Clinical Dementia Rating, Alzheimer's disease, Serum, CCL11, CCL2, Alzheimer's Association, PET, IL-6, Brain, Melinda French Gates, Biomarker, Inflammation, Dementia, Trial of the century, COYA, Cerebral cortex, Cognitive Function Scanner, ADAS-Cog, Bill & Melinda Gates Foundation, Patient, Blood, Interleukin 6, Microglia, Cytokine, Mini–Mental State Examination, Therapy, Positron emission tomography, Nerve, MMSE, ALS, Conference, Interleukin, Neuroinflammation, Pharmaceutical industry, Vaccine, Medical imaging, TSPO

- Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.

Key Points: 
  • - Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.
  • Meaningful reductions in neuroinflammation were observed throughout the cerebral cortex including hippocampal regions following treatment with COYA 301, which correlated with improvement in cognitive function in this patient.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • "We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need.

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
星期四, 七月 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)

Retrieved on: 
星期三, 六月 7, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Serum, CCL11, CCL2, PET, IL-6, Brain, Biomarker, Inflammation, Dementia, Trial of the century, COYA, Cerebral cortex, Jungian cognitive functions, ADAS-Cog, Patient, Coya, Blood, Microglia, Cytokine, Therapy, Nerve, ALS, MMSE, Conference, Medical imaging, TSPO

The open-label study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.

Key Points: 
  • The open-label study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • In addition to COYA 301 administration resulting in a statistically significant reduction of blood biomarkers CCL11, CCL2, and IL-15.
  • The PET scan after the last cycle of COYA 301 showed marked reduction in TSPO binding across the brain representing lowered inflammation.

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
星期四, 五月 25, 2023
Human, CD47, PD, AE, CCL2, Bachelor of Medicine, Bachelor of Surgery, Aes, Clinical trial, RECIST, Cancer, Mirvetuximab soravtansine, PROC, ASCO, Monocyte, Patient, Autoimmune disease, CCL20, CCL22, CD4, IRR, Safety, Generic drug, Pharmaceutical industry, Palladium, Vaccine, CD40

AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of complete dose-escalation data from the Phase 1A monotherapy clinical trial of SL-172154 in PROC. These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023.

Key Points: 
  • These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023.
  • Our ongoing clinical trial of SL-172154 in combination with liposomal doxorubicin remains on track, and we expect to share initial data midyear.
  • Session Date and Time: Monday, June 5 at 1:15 p.m. CT
    SL-172154 was generally well tolerated in heavily pretreated PROC patients.
  • Maximal CD47 and CD40 target engagement and CD40-dependent PD effects were observed with ≥ 3 mg/kg of SL-172154.

Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease

Retrieved on: 
星期二, 五月 16, 2023
Mental Health, Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, General Health, Science, Houston Methodist Hospital, Serum, CCL11, Chemokine, CCL2, Survival, Therapy, Brain, Biomarker, Inflammation, Dementia, COYA, Regulatory T cell, Cognitive Function Scanner, ADAS-Cog, HIV disease progression rates, Patient, Coya, Poster, Cytokine, Next Generation, AD, ALS, Conference, MMSE, SD, Pharmaceutical industry

The study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.

Key Points: 
  • The study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.
  • The patients were treated with five-day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • Treg function and numbers, serum biomarkers of inflammation, and cognitive functioning as measured by the ADAS-Cog, CDR-SB and MMSE assessment tools were evaluated.
  • Mean (SD) Treg suppressive function was 46.61% (7.74) at baseline, and significantly increased to 79.5 % (20.55) at the end of treatment (p=0.003).

FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients

Retrieved on: 
星期二, 四月 25, 2023
FDA, General Health, Health, Injection, Grey, Disability, CCL2, Quality of life, Research, Biomarker, Cerebrospinal fluid, Walking, Dementia, Tisch, MS, MMP9, Patient, B cell, Phase, Inflammation, Pharmaceutical industry, Medical device

The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.

Key Points: 
  • The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.
  • Additionally, patients who received the stem cell treatments showed improved bladder function, with 69% of patients showing improved post-void residual volume.
  • “These findings are unprecedented in the realm of researching stem cells as a treatment pathway for progressive MS patients.
  • The Phase II trial began in 2018 and was a randomized, double-blind, placebo-controlled clinical study with 54 patients.

Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

Retrieved on: 
星期四, 一月 12, 2023
CCL2, Presbyopia, Chemokine, BAK, Cytokine, Tufts Medical Center, ELISA, Glaucoma, Medical Affairs Bureau, Patient, Mydriasis, Gene expression, Inflammation, IL6, Interim, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Ophthalmology

Unfortunately, patients treated with BAK preserved glaucoma medications often suffer inflammatory side effects and develop subsequent ocular surface disease.

Key Points: 
  • Unfortunately, patients treated with BAK preserved glaucoma medications often suffer inflammatory side effects and develop subsequent ocular surface disease.
  • “Chronic treatment of glaucoma with BAK preserved topical ophthalmic medications introduces ocular surface stress and may trigger a vicious cycle of inflammation,” said Dr. Hamrah.
  • In these early findings, the Optejet® technology appears better than latanoprost+BAK administered via standard drops in reducing inflammatory processes and pathways.
  • Julie Whitcomb, PhD, Sr. Director of Medical Affairs at Eyenovia, commented, “The Optejet® Technology shows lower levels of proinflammatory cytokines and chemokines than standard drops.